glp-1 and neuroinflammation drugs calm inflammation beyond diabetes weight loss Frontiers | The immunomodulatory effects

The European green light is a major commercial prize, as the continent represents one of the largest and most lucrative markets for prescription medicines in the world, and demand for effective obesity treatments has surged in recent years

Key considerations from available evidence: No direct hormonal mechanism linking tirzepatide to menstrual disruption has been identified Metabolic improvements (reduced insulin resistance, decreased androgens) may benefit women with PCOS The magnitude and rapidity of weight loss correlate with likelihood of temporary menstrual changes Long-term data on reproductive outcomes remain limited Healthcare providers should counsel women of reproductive age about potential menstrual changes when initiating tirzepatide

We described the cumulative incidence of treatment discontinuation in all patients and treatment reinitiation among those who discontinued treatment using the AalenJohansen estimator

CorMedix expects DefenCath to be available in the inpatient setting in the first quarter of 2024

4.2 Sleep Quality Poor or inconsistent sleep disrupts the balance of hunger and satiety hormonesincluding GLP-1, ghrelin and leptin

& Wadden, T